FocaL Mass Drug Administration for Vivax Malaria Elimination
Status:
Not yet recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
FLAME is an open-label cluster-randomized controlled trial that aims to determine the
effectiveness of focal mass drug administration (fMDA) to reduce the incidence of Plasmodium
vivax malaria in the Loreto Department in Peru. Standard interventions, including symptomatic
and asymptomatic screening for malaria infections, provision of insecticide-treated bednets,
and environmental transmission monitoring, will be compared to clusters of villages
randomized to receive anti-malarial drugs.
Phase:
Phase 3
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Eijkman Oxford Clinical Research Unit, Indonesia Menzies School of Health Research National Institute of Allergy and Infectious Diseases (NIAID) PATH Stanford University Universidad Peruana Cayetano Heredia- subcontractor to UCSF as local Sponsor